Global Mirabegron Sustained-release Tablets Market Growth 2026-2032
The global Mirabegron Sustained-release Tablets market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Mirabegron sustained-release tablets are designed to provide a controlled release of the medication over an extended period, which helps maintain stable levels of mirabegron in the bloodstream.This formulation is used to treat overactive bladder (OAB) symptoms, including frequent urination, urgency, and urinary incontinence.
United States market for Mirabegron Sustained-release Tablets is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Mirabegron Sustained-release Tablets is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Mirabegron Sustained-release Tablets is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Mirabegron Sustained-release Tablets players cover Astellas Pharma, Zydus Lifesciences, Lupin Pharmaceuticals, Alkem Laboratories, Chia Tai Tianqing Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Mirabegron Sustained-release Tablets Industry Forecast? looks at past sales and reviews total world Mirabegron Sustained-release Tablets sales in 2025, providing a comprehensive analysis by region and market sector of projected Mirabegron Sustained-release Tablets sales for 2026 through 2032. With Mirabegron Sustained-release Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mirabegron Sustained-release Tablets industry.
This Insight Report provides a comprehensive analysis of the global Mirabegron Sustained-release Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mirabegron Sustained-release Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Mirabegron Sustained-release Tablets market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mirabegron Sustained-release Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mirabegron Sustained-release Tablets.
This report presents a comprehensive overview, market shares, and growth opportunities of Mirabegron Sustained-release Tablets market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Mirabegron Sustained-release Tablets market?
What factors are driving Mirabegron Sustained-release Tablets market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Mirabegron Sustained-release Tablets market opportunities vary by end market size?
How does Mirabegron Sustained-release Tablets break out by Type, by Application?
Mirabegron sustained-release tablets are designed to provide a controlled release of the medication over an extended period, which helps maintain stable levels of mirabegron in the bloodstream.This formulation is used to treat overactive bladder (OAB) symptoms, including frequent urination, urgency, and urinary incontinence.
United States market for Mirabegron Sustained-release Tablets is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Mirabegron Sustained-release Tablets is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Mirabegron Sustained-release Tablets is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Mirabegron Sustained-release Tablets players cover Astellas Pharma, Zydus Lifesciences, Lupin Pharmaceuticals, Alkem Laboratories, Chia Tai Tianqing Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Mirabegron Sustained-release Tablets Industry Forecast? looks at past sales and reviews total world Mirabegron Sustained-release Tablets sales in 2025, providing a comprehensive analysis by region and market sector of projected Mirabegron Sustained-release Tablets sales for 2026 through 2032. With Mirabegron Sustained-release Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mirabegron Sustained-release Tablets industry.
This Insight Report provides a comprehensive analysis of the global Mirabegron Sustained-release Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mirabegron Sustained-release Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Mirabegron Sustained-release Tablets market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mirabegron Sustained-release Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mirabegron Sustained-release Tablets.
This report presents a comprehensive overview, market shares, and growth opportunities of Mirabegron Sustained-release Tablets market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 25mg per Tablet
- 50mg per Tablet
- Hospital and Clinic
- Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Astellas Pharma
- Zydus Lifesciences
- Lupin Pharmaceuticals
- Alkem Laboratories
- Chia Tai Tianqing Pharmaceutical
- Zhejiang Huayi Pharmaceutical
- China Resources Pharmaceutical
- Jiangxi Shanxiang Pharmaceutical
- CSPC Pharmaceutical
- Qilu Pharmaceutical
- Jiangsu Huayang Pharmaceutical
- Sichuan Gowell Pharmaceutical
- Shenzhen Main Luck Pharmaceuticals
What is the 10-year outlook for the global Mirabegron Sustained-release Tablets market?
What factors are driving Mirabegron Sustained-release Tablets market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Mirabegron Sustained-release Tablets market opportunities vary by end market size?
How does Mirabegron Sustained-release Tablets break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Mirabegron Sustained-release Tablets Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Mirabegron Sustained-release Tablets by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Mirabegron Sustained-release Tablets by Country/Region, 2021, 2025 & 2032
2.2 Mirabegron Sustained-release Tablets Segment by Type
2.2.1 25mg per Tablet
2.2.2 50mg per Tablet
2.2.3 Mirabegron Sustained-release Tablets Sales by Type
2.2.3.1 Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2026)
2.2.3.2 Global Mirabegron Sustained-release Tablets Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Mirabegron Sustained-release Tablets Sale Price by Type (2021-2026)
2.3 Mirabegron Sustained-release Tablets Segment by Application
2.3.1 Hospital and Clinic
2.3.2 Pharmacy
2.3.3 Other
2.3.4 Mirabegron Sustained-release Tablets Sales by Application
2.3.4.1 Global Mirabegron Sustained-release Tablets Sale Market Share by Application (2021-2026)
2.3.4.2 Global Mirabegron Sustained-release Tablets Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Mirabegron Sustained-release Tablets Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Mirabegron Sustained-release Tablets Breakdown Data by Company
3.1.1 Global Mirabegron Sustained-release Tablets Annual Sales by Company (2021-2026)
3.1.2 Global Mirabegron Sustained-release Tablets Sales Market Share by Company (2021-2026)
3.2 Global Mirabegron Sustained-release Tablets Annual Revenue by Company (2021-2026)
3.2.1 Global Mirabegron Sustained-release Tablets Revenue by Company (2021-2026)
3.2.2 Global Mirabegron Sustained-release Tablets Revenue Market Share by Company (2021-2026)
3.3 Global Mirabegron Sustained-release Tablets Sale Price by Company
3.4 Key Manufacturers Mirabegron Sustained-release Tablets Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Mirabegron Sustained-release Tablets Product Location Distribution
3.4.2 Players Mirabegron Sustained-release Tablets Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MIRABEGRON SUSTAINED-RELEASE TABLETS BY GEOGRAPHIC REGION
4.1 World Historic Mirabegron Sustained-release Tablets Market Size by Geographic Region (2021-2026)
4.1.1 Global Mirabegron Sustained-release Tablets Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Mirabegron Sustained-release Tablets Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Mirabegron Sustained-release Tablets Market Size by Country/Region (2021-2026)
4.2.1 Global Mirabegron Sustained-release Tablets Annual Sales by Country/Region (2021-2026)
4.2.2 Global Mirabegron Sustained-release Tablets Annual Revenue by Country/Region (2021-2026)
4.3 Americas Mirabegron Sustained-release Tablets Sales Growth
4.4 APAC Mirabegron Sustained-release Tablets Sales Growth
4.5 Europe Mirabegron Sustained-release Tablets Sales Growth
4.6 Middle East & Africa Mirabegron Sustained-release Tablets Sales Growth
5 AMERICAS
5.1 Americas Mirabegron Sustained-release Tablets Sales by Country
5.1.1 Americas Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
5.1.2 Americas Mirabegron Sustained-release Tablets Revenue by Country (2021-2026)
5.2 Americas Mirabegron Sustained-release Tablets Sales by Type (2021-2026)
5.3 Americas Mirabegron Sustained-release Tablets Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Mirabegron Sustained-release Tablets Sales by Region
6.1.1 APAC Mirabegron Sustained-release Tablets Sales by Region (2021-2026)
6.1.2 APAC Mirabegron Sustained-release Tablets Revenue by Region (2021-2026)
6.2 APAC Mirabegron Sustained-release Tablets Sales by Type (2021-2026)
6.3 APAC Mirabegron Sustained-release Tablets Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Mirabegron Sustained-release Tablets by Country
7.1.1 Europe Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
7.1.2 Europe Mirabegron Sustained-release Tablets Revenue by Country (2021-2026)
7.2 Europe Mirabegron Sustained-release Tablets Sales by Type (2021-2026)
7.3 Europe Mirabegron Sustained-release Tablets Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Mirabegron Sustained-release Tablets by Country
8.1.1 Middle East & Africa Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
8.1.2 Middle East & Africa Mirabegron Sustained-release Tablets Revenue by Country (2021-2026)
8.2 Middle East & Africa Mirabegron Sustained-release Tablets Sales by Type (2021-2026)
8.3 Middle East & Africa Mirabegron Sustained-release Tablets Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Mirabegron Sustained-release Tablets
10.3 Manufacturing Process Analysis of Mirabegron Sustained-release Tablets
10.4 Industry Chain Structure of Mirabegron Sustained-release Tablets
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Mirabegron Sustained-release Tablets Distributors
11.3 Mirabegron Sustained-release Tablets Customer
12 WORLD FORECAST REVIEW FOR MIRABEGRON SUSTAINED-RELEASE TABLETS BY GEOGRAPHIC REGION
12.1 Global Mirabegron Sustained-release Tablets Market Size Forecast by Region
12.1.1 Global Mirabegron Sustained-release Tablets Forecast by Region (2027-2032)
12.1.2 Global Mirabegron Sustained-release Tablets Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Mirabegron Sustained-release Tablets Forecast by Type (2027-2032)
12.7 Global Mirabegron Sustained-release Tablets Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma
13.1.1 Astellas Pharma Company Information
13.1.2 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.1.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Astellas Pharma Main Business Overview
13.1.5 Astellas Pharma Latest Developments
13.2 Zydus Lifesciences
13.2.1 Zydus Lifesciences Company Information
13.2.2 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.2.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Zydus Lifesciences Main Business Overview
13.2.5 Zydus Lifesciences Latest Developments
13.3 Lupin Pharmaceuticals
13.3.1 Lupin Pharmaceuticals Company Information
13.3.2 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Lupin Pharmaceuticals Main Business Overview
13.3.5 Lupin Pharmaceuticals Latest Developments
13.4 Alkem Laboratories
13.4.1 Alkem Laboratories Company Information
13.4.2 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.4.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Alkem Laboratories Main Business Overview
13.4.5 Alkem Laboratories Latest Developments
13.5 Chia Tai Tianqing Pharmaceutical
13.5.1 Chia Tai Tianqing Pharmaceutical Company Information
13.5.2 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.5.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.5.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.6 Zhejiang Huayi Pharmaceutical
13.6.1 Zhejiang Huayi Pharmaceutical Company Information
13.6.2 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.6.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Zhejiang Huayi Pharmaceutical Main Business Overview
13.6.5 Zhejiang Huayi Pharmaceutical Latest Developments
13.7 China Resources Pharmaceutical
13.7.1 China Resources Pharmaceutical Company Information
13.7.2 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.7.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 China Resources Pharmaceutical Main Business Overview
13.7.5 China Resources Pharmaceutical Latest Developments
13.8 Jiangxi Shanxiang Pharmaceutical
13.8.1 Jiangxi Shanxiang Pharmaceutical Company Information
13.8.2 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.8.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Jiangxi Shanxiang Pharmaceutical Main Business Overview
13.8.5 Jiangxi Shanxiang Pharmaceutical Latest Developments
13.9 CSPC Pharmaceutical
13.9.1 CSPC Pharmaceutical Company Information
13.9.2 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.9.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 CSPC Pharmaceutical Main Business Overview
13.9.5 CSPC Pharmaceutical Latest Developments
13.10 Qilu Pharmaceutical
13.10.1 Qilu Pharmaceutical Company Information
13.10.2 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.10.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Qilu Pharmaceutical Main Business Overview
13.10.5 Qilu Pharmaceutical Latest Developments
13.11 Jiangsu Huayang Pharmaceutical
13.11.1 Jiangsu Huayang Pharmaceutical Company Information
13.11.2 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.11.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Jiangsu Huayang Pharmaceutical Main Business Overview
13.11.5 Jiangsu Huayang Pharmaceutical Latest Developments
13.12 Sichuan Gowell Pharmaceutical
13.12.1 Sichuan Gowell Pharmaceutical Company Information
13.12.2 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.12.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sichuan Gowell Pharmaceutical Main Business Overview
13.12.5 Sichuan Gowell Pharmaceutical Latest Developments
13.13 Shenzhen Main Luck Pharmaceuticals
13.13.1 Shenzhen Main Luck Pharmaceuticals Company Information
13.13.2 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.13.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Shenzhen Main Luck Pharmaceuticals Main Business Overview
13.13.5 Shenzhen Main Luck Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Mirabegron Sustained-release Tablets Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Mirabegron Sustained-release Tablets by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Mirabegron Sustained-release Tablets by Country/Region, 2021, 2025 & 2032
2.2 Mirabegron Sustained-release Tablets Segment by Type
2.2.1 25mg per Tablet
2.2.2 50mg per Tablet
2.2.3 Mirabegron Sustained-release Tablets Sales by Type
2.2.3.1 Global Mirabegron Sustained-release Tablets Sales Market Share by Type (2021-2026)
2.2.3.2 Global Mirabegron Sustained-release Tablets Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Mirabegron Sustained-release Tablets Sale Price by Type (2021-2026)
2.3 Mirabegron Sustained-release Tablets Segment by Application
2.3.1 Hospital and Clinic
2.3.2 Pharmacy
2.3.3 Other
2.3.4 Mirabegron Sustained-release Tablets Sales by Application
2.3.4.1 Global Mirabegron Sustained-release Tablets Sale Market Share by Application (2021-2026)
2.3.4.2 Global Mirabegron Sustained-release Tablets Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Mirabegron Sustained-release Tablets Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Mirabegron Sustained-release Tablets Breakdown Data by Company
3.1.1 Global Mirabegron Sustained-release Tablets Annual Sales by Company (2021-2026)
3.1.2 Global Mirabegron Sustained-release Tablets Sales Market Share by Company (2021-2026)
3.2 Global Mirabegron Sustained-release Tablets Annual Revenue by Company (2021-2026)
3.2.1 Global Mirabegron Sustained-release Tablets Revenue by Company (2021-2026)
3.2.2 Global Mirabegron Sustained-release Tablets Revenue Market Share by Company (2021-2026)
3.3 Global Mirabegron Sustained-release Tablets Sale Price by Company
3.4 Key Manufacturers Mirabegron Sustained-release Tablets Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Mirabegron Sustained-release Tablets Product Location Distribution
3.4.2 Players Mirabegron Sustained-release Tablets Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MIRABEGRON SUSTAINED-RELEASE TABLETS BY GEOGRAPHIC REGION
4.1 World Historic Mirabegron Sustained-release Tablets Market Size by Geographic Region (2021-2026)
4.1.1 Global Mirabegron Sustained-release Tablets Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Mirabegron Sustained-release Tablets Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Mirabegron Sustained-release Tablets Market Size by Country/Region (2021-2026)
4.2.1 Global Mirabegron Sustained-release Tablets Annual Sales by Country/Region (2021-2026)
4.2.2 Global Mirabegron Sustained-release Tablets Annual Revenue by Country/Region (2021-2026)
4.3 Americas Mirabegron Sustained-release Tablets Sales Growth
4.4 APAC Mirabegron Sustained-release Tablets Sales Growth
4.5 Europe Mirabegron Sustained-release Tablets Sales Growth
4.6 Middle East & Africa Mirabegron Sustained-release Tablets Sales Growth
5 AMERICAS
5.1 Americas Mirabegron Sustained-release Tablets Sales by Country
5.1.1 Americas Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
5.1.2 Americas Mirabegron Sustained-release Tablets Revenue by Country (2021-2026)
5.2 Americas Mirabegron Sustained-release Tablets Sales by Type (2021-2026)
5.3 Americas Mirabegron Sustained-release Tablets Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Mirabegron Sustained-release Tablets Sales by Region
6.1.1 APAC Mirabegron Sustained-release Tablets Sales by Region (2021-2026)
6.1.2 APAC Mirabegron Sustained-release Tablets Revenue by Region (2021-2026)
6.2 APAC Mirabegron Sustained-release Tablets Sales by Type (2021-2026)
6.3 APAC Mirabegron Sustained-release Tablets Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Mirabegron Sustained-release Tablets by Country
7.1.1 Europe Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
7.1.2 Europe Mirabegron Sustained-release Tablets Revenue by Country (2021-2026)
7.2 Europe Mirabegron Sustained-release Tablets Sales by Type (2021-2026)
7.3 Europe Mirabegron Sustained-release Tablets Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Mirabegron Sustained-release Tablets by Country
8.1.1 Middle East & Africa Mirabegron Sustained-release Tablets Sales by Country (2021-2026)
8.1.2 Middle East & Africa Mirabegron Sustained-release Tablets Revenue by Country (2021-2026)
8.2 Middle East & Africa Mirabegron Sustained-release Tablets Sales by Type (2021-2026)
8.3 Middle East & Africa Mirabegron Sustained-release Tablets Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Mirabegron Sustained-release Tablets
10.3 Manufacturing Process Analysis of Mirabegron Sustained-release Tablets
10.4 Industry Chain Structure of Mirabegron Sustained-release Tablets
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Mirabegron Sustained-release Tablets Distributors
11.3 Mirabegron Sustained-release Tablets Customer
12 WORLD FORECAST REVIEW FOR MIRABEGRON SUSTAINED-RELEASE TABLETS BY GEOGRAPHIC REGION
12.1 Global Mirabegron Sustained-release Tablets Market Size Forecast by Region
12.1.1 Global Mirabegron Sustained-release Tablets Forecast by Region (2027-2032)
12.1.2 Global Mirabegron Sustained-release Tablets Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Mirabegron Sustained-release Tablets Forecast by Type (2027-2032)
12.7 Global Mirabegron Sustained-release Tablets Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Astellas Pharma
13.1.1 Astellas Pharma Company Information
13.1.2 Astellas Pharma Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.1.3 Astellas Pharma Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Astellas Pharma Main Business Overview
13.1.5 Astellas Pharma Latest Developments
13.2 Zydus Lifesciences
13.2.1 Zydus Lifesciences Company Information
13.2.2 Zydus Lifesciences Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.2.3 Zydus Lifesciences Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Zydus Lifesciences Main Business Overview
13.2.5 Zydus Lifesciences Latest Developments
13.3 Lupin Pharmaceuticals
13.3.1 Lupin Pharmaceuticals Company Information
13.3.2 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.3.3 Lupin Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Lupin Pharmaceuticals Main Business Overview
13.3.5 Lupin Pharmaceuticals Latest Developments
13.4 Alkem Laboratories
13.4.1 Alkem Laboratories Company Information
13.4.2 Alkem Laboratories Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.4.3 Alkem Laboratories Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Alkem Laboratories Main Business Overview
13.4.5 Alkem Laboratories Latest Developments
13.5 Chia Tai Tianqing Pharmaceutical
13.5.1 Chia Tai Tianqing Pharmaceutical Company Information
13.5.2 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.5.3 Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.5.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.6 Zhejiang Huayi Pharmaceutical
13.6.1 Zhejiang Huayi Pharmaceutical Company Information
13.6.2 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.6.3 Zhejiang Huayi Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Zhejiang Huayi Pharmaceutical Main Business Overview
13.6.5 Zhejiang Huayi Pharmaceutical Latest Developments
13.7 China Resources Pharmaceutical
13.7.1 China Resources Pharmaceutical Company Information
13.7.2 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.7.3 China Resources Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 China Resources Pharmaceutical Main Business Overview
13.7.5 China Resources Pharmaceutical Latest Developments
13.8 Jiangxi Shanxiang Pharmaceutical
13.8.1 Jiangxi Shanxiang Pharmaceutical Company Information
13.8.2 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.8.3 Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Jiangxi Shanxiang Pharmaceutical Main Business Overview
13.8.5 Jiangxi Shanxiang Pharmaceutical Latest Developments
13.9 CSPC Pharmaceutical
13.9.1 CSPC Pharmaceutical Company Information
13.9.2 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.9.3 CSPC Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 CSPC Pharmaceutical Main Business Overview
13.9.5 CSPC Pharmaceutical Latest Developments
13.10 Qilu Pharmaceutical
13.10.1 Qilu Pharmaceutical Company Information
13.10.2 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.10.3 Qilu Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Qilu Pharmaceutical Main Business Overview
13.10.5 Qilu Pharmaceutical Latest Developments
13.11 Jiangsu Huayang Pharmaceutical
13.11.1 Jiangsu Huayang Pharmaceutical Company Information
13.11.2 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.11.3 Jiangsu Huayang Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Jiangsu Huayang Pharmaceutical Main Business Overview
13.11.5 Jiangsu Huayang Pharmaceutical Latest Developments
13.12 Sichuan Gowell Pharmaceutical
13.12.1 Sichuan Gowell Pharmaceutical Company Information
13.12.2 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.12.3 Sichuan Gowell Pharmaceutical Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sichuan Gowell Pharmaceutical Main Business Overview
13.12.5 Sichuan Gowell Pharmaceutical Latest Developments
13.13 Shenzhen Main Luck Pharmaceuticals
13.13.1 Shenzhen Main Luck Pharmaceuticals Company Information
13.13.2 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Product Portfolios and Specifications
13.13.3 Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-release Tablets Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Shenzhen Main Luck Pharmaceuticals Main Business Overview
13.13.5 Shenzhen Main Luck Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Mirabegron Sustained-releaseTablets Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Mirabegron Sustained-releaseTablets Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 25mg perTablet
Table 4. Major Players of 50mg perTablet
Table 5. Global Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)
Table 6. Global Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)
Table 7. Global Mirabegron Sustained-releaseTablets Revenue by Type (2021-2026) & ($ million)
Table 8. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Type (2021-2026)
Table 9. Global Mirabegron Sustained-releaseTablets Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Mirabegron Sustained-releaseTablets Sale by Application (2021-2026) & (K Units)
Table 11. Global Mirabegron Sustained-releaseTablets Sale Market Share by Application (2021-2026)
Table 12. Global Mirabegron Sustained-releaseTablets Revenue by Application (2021-2026) & ($ million)
Table 13. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Application (2021-2026)
Table 14. Global Mirabegron Sustained-releaseTablets Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Mirabegron Sustained-releaseTablets Sales by Company (2021-2026) & (K Units)
Table 16. Global Mirabegron Sustained-releaseTablets Sales Market Share by Company (2021-2026)
Table 17. Global Mirabegron Sustained-releaseTablets Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Company (2021-2026)
Table 19. Global Mirabegron Sustained-releaseTablets Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Mirabegron Sustained-releaseTablets Producing Area Distribution and Sales Area
Table 21. Players Mirabegron Sustained-releaseTablets Products Offered
Table 22. Mirabegron Sustained-releaseTablets Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Mirabegron Sustained-releaseTablets Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Mirabegron Sustained-releaseTablets Sales Market Share Geographic Region (2021-2026)
Table 27. Global Mirabegron Sustained-releaseTablets Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Mirabegron Sustained-releaseTablets Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Mirabegron Sustained-releaseTablets Sales Market Share by Country/Region (2021-2026)
Table 31. Global Mirabegron Sustained-releaseTablets Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Mirabegron Sustained-releaseTablets Sales by Country (2021-2026) & (K Units)
Table 34. Americas Mirabegron Sustained-releaseTablets Sales Market Share by Country (2021-2026)
Table 35. Americas Mirabegron Sustained-releaseTablets Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)
Table 37. Americas Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)
Table 38. APAC Mirabegron Sustained-releaseTablets Sales by Region (2021-2026) & (K Units)
Table 39. APAC Mirabegron Sustained-releaseTablets Sales Market Share by Region (2021-2026)
Table 40. APAC Mirabegron Sustained-releaseTablets Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)
Table 42. APAC Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)
Table 43. Europe Mirabegron Sustained-releaseTablets Sales by Country (2021-2026) & (K Units)
Table 44. Europe Mirabegron Sustained-releaseTablets Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)
Table 46. Europe Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Mirabegron Sustained-releaseTablets Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Mirabegron Sustained-releaseTablets Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Mirabegron Sustained-releaseTablets
Table 52. Key Market Challenges & Risks of Mirabegron Sustained-releaseTablets
Table 53. Key Industry Trends of Mirabegron Sustained-releaseTablets
Table 54. Mirabegron Sustained-releaseTablets Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Mirabegron Sustained-releaseTablets Distributors List
Table 57. Mirabegron Sustained-releaseTablets Customer List
Table 58. Global Mirabegron Sustained-releaseTablets Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Mirabegron Sustained-releaseTablets Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Mirabegron Sustained-releaseTablets Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Mirabegron Sustained-releaseTablets Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Mirabegron Sustained-releaseTablets Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Mirabegron Sustained-releaseTablets Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Mirabegron Sustained-releaseTablets Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Mirabegron Sustained-releaseTablets Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Mirabegron Sustained-releaseTablets Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Mirabegron Sustained-releaseTablets Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Mirabegron Sustained-releaseTablets Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Mirabegron Sustained-releaseTablets Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Mirabegron Sustained-releaseTablets Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Astellas Pharma Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 73. Astellas Pharma Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 74. Astellas Pharma Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Astellas Pharma Main Business
Table 76. Astellas Pharma Latest Developments
Table 77. Zydus Lifesciences Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 78. Zydus Lifesciences Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 79. Zydus Lifesciences Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Zydus Lifesciences Main Business
Table 81. Zydus Lifesciences Latest Developments
Table 82. Lupin Pharmaceuticals Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 83. Lupin Pharmaceuticals Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 84. Lupin Pharmaceuticals Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Lupin Pharmaceuticals Main Business
Table 86. Lupin Pharmaceuticals Latest Developments
Table 87. Alkem Laboratories Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 88. Alkem Laboratories Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 89. Alkem Laboratories Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Alkem Laboratories Main Business
Table 91. Alkem Laboratories Latest Developments
Table 92. Chia Tai Tianqing Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 93. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 94. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Chia Tai Tianqing Pharmaceutical Main Business
Table 96. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 97. Zhejiang Huayi Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 98. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 99. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Zhejiang Huayi Pharmaceutical Main Business
Table 101. Zhejiang Huayi Pharmaceutical Latest Developments
Table 102. China Resources Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 103. China Resources Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 104. China Resources Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. China Resources Pharmaceutical Main Business
Table 106. China Resources Pharmaceutical Latest Developments
Table 107. Jiangxi Shanxiang Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 108. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 109. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Jiangxi Shanxiang Pharmaceutical Main Business
Table 111. Jiangxi Shanxiang Pharmaceutical Latest Developments
Table 112. CSPC Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 113. CSPC Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 114. CSPC Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. CSPC Pharmaceutical Main Business
Table 116. CSPC Pharmaceutical Latest Developments
Table 117. Qilu Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 118. Qilu Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 119. Qilu Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Qilu Pharmaceutical Main Business
Table 121. Qilu Pharmaceutical Latest Developments
Table 122. Jiangsu Huayang Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 123. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 124. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Jiangsu Huayang Pharmaceutical Main Business
Table 126. Jiangsu Huayang Pharmaceutical Latest Developments
Table 127. Sichuan Gowell Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 128. Sichuan Gowell Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 129. Sichuan Gowell Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Sichuan Gowell Pharmaceutical Main Business
Table 131. Sichuan Gowell Pharmaceutical Latest Developments
Table 132. Shenzhen Main Luck Pharmaceuticals Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 133. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 134. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Shenzhen Main Luck Pharmaceuticals Main Business
Table 136. Shenzhen Main Luck Pharmaceuticals Latest Developments
Table 1. Mirabegron Sustained-releaseTablets Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Mirabegron Sustained-releaseTablets Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 25mg perTablet
Table 4. Major Players of 50mg perTablet
Table 5. Global Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)
Table 6. Global Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)
Table 7. Global Mirabegron Sustained-releaseTablets Revenue by Type (2021-2026) & ($ million)
Table 8. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Type (2021-2026)
Table 9. Global Mirabegron Sustained-releaseTablets Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Mirabegron Sustained-releaseTablets Sale by Application (2021-2026) & (K Units)
Table 11. Global Mirabegron Sustained-releaseTablets Sale Market Share by Application (2021-2026)
Table 12. Global Mirabegron Sustained-releaseTablets Revenue by Application (2021-2026) & ($ million)
Table 13. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Application (2021-2026)
Table 14. Global Mirabegron Sustained-releaseTablets Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Mirabegron Sustained-releaseTablets Sales by Company (2021-2026) & (K Units)
Table 16. Global Mirabegron Sustained-releaseTablets Sales Market Share by Company (2021-2026)
Table 17. Global Mirabegron Sustained-releaseTablets Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Company (2021-2026)
Table 19. Global Mirabegron Sustained-releaseTablets Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Mirabegron Sustained-releaseTablets Producing Area Distribution and Sales Area
Table 21. Players Mirabegron Sustained-releaseTablets Products Offered
Table 22. Mirabegron Sustained-releaseTablets Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Mirabegron Sustained-releaseTablets Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Mirabegron Sustained-releaseTablets Sales Market Share Geographic Region (2021-2026)
Table 27. Global Mirabegron Sustained-releaseTablets Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Mirabegron Sustained-releaseTablets Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Mirabegron Sustained-releaseTablets Sales Market Share by Country/Region (2021-2026)
Table 31. Global Mirabegron Sustained-releaseTablets Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Mirabegron Sustained-releaseTablets Sales by Country (2021-2026) & (K Units)
Table 34. Americas Mirabegron Sustained-releaseTablets Sales Market Share by Country (2021-2026)
Table 35. Americas Mirabegron Sustained-releaseTablets Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)
Table 37. Americas Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)
Table 38. APAC Mirabegron Sustained-releaseTablets Sales by Region (2021-2026) & (K Units)
Table 39. APAC Mirabegron Sustained-releaseTablets Sales Market Share by Region (2021-2026)
Table 40. APAC Mirabegron Sustained-releaseTablets Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)
Table 42. APAC Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)
Table 43. Europe Mirabegron Sustained-releaseTablets Sales by Country (2021-2026) & (K Units)
Table 44. Europe Mirabegron Sustained-releaseTablets Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)
Table 46. Europe Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Mirabegron Sustained-releaseTablets Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Mirabegron Sustained-releaseTablets Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Mirabegron Sustained-releaseTablets Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Mirabegron Sustained-releaseTablets Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Mirabegron Sustained-releaseTablets
Table 52. Key Market Challenges & Risks of Mirabegron Sustained-releaseTablets
Table 53. Key Industry Trends of Mirabegron Sustained-releaseTablets
Table 54. Mirabegron Sustained-releaseTablets Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Mirabegron Sustained-releaseTablets Distributors List
Table 57. Mirabegron Sustained-releaseTablets Customer List
Table 58. Global Mirabegron Sustained-releaseTablets Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Mirabegron Sustained-releaseTablets Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Mirabegron Sustained-releaseTablets Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Mirabegron Sustained-releaseTablets Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Mirabegron Sustained-releaseTablets Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Mirabegron Sustained-releaseTablets Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Mirabegron Sustained-releaseTablets Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Mirabegron Sustained-releaseTablets Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Mirabegron Sustained-releaseTablets Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Mirabegron Sustained-releaseTablets Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Mirabegron Sustained-releaseTablets Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Mirabegron Sustained-releaseTablets Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Mirabegron Sustained-releaseTablets Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Astellas Pharma Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 73. Astellas Pharma Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 74. Astellas Pharma Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Astellas Pharma Main Business
Table 76. Astellas Pharma Latest Developments
Table 77. Zydus Lifesciences Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 78. Zydus Lifesciences Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 79. Zydus Lifesciences Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Zydus Lifesciences Main Business
Table 81. Zydus Lifesciences Latest Developments
Table 82. Lupin Pharmaceuticals Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 83. Lupin Pharmaceuticals Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 84. Lupin Pharmaceuticals Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Lupin Pharmaceuticals Main Business
Table 86. Lupin Pharmaceuticals Latest Developments
Table 87. Alkem Laboratories Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 88. Alkem Laboratories Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 89. Alkem Laboratories Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Alkem Laboratories Main Business
Table 91. Alkem Laboratories Latest Developments
Table 92. Chia Tai Tianqing Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 93. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 94. Chia Tai Tianqing Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Chia Tai Tianqing Pharmaceutical Main Business
Table 96. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 97. Zhejiang Huayi Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 98. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 99. Zhejiang Huayi Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Zhejiang Huayi Pharmaceutical Main Business
Table 101. Zhejiang Huayi Pharmaceutical Latest Developments
Table 102. China Resources Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 103. China Resources Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 104. China Resources Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. China Resources Pharmaceutical Main Business
Table 106. China Resources Pharmaceutical Latest Developments
Table 107. Jiangxi Shanxiang Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 108. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 109. Jiangxi Shanxiang Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Jiangxi Shanxiang Pharmaceutical Main Business
Table 111. Jiangxi Shanxiang Pharmaceutical Latest Developments
Table 112. CSPC Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 113. CSPC Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 114. CSPC Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. CSPC Pharmaceutical Main Business
Table 116. CSPC Pharmaceutical Latest Developments
Table 117. Qilu Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 118. Qilu Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 119. Qilu Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Qilu Pharmaceutical Main Business
Table 121. Qilu Pharmaceutical Latest Developments
Table 122. Jiangsu Huayang Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 123. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 124. Jiangsu Huayang Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Jiangsu Huayang Pharmaceutical Main Business
Table 126. Jiangsu Huayang Pharmaceutical Latest Developments
Table 127. Sichuan Gowell Pharmaceutical Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 128. Sichuan Gowell Pharmaceutical Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 129. Sichuan Gowell Pharmaceutical Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Sichuan Gowell Pharmaceutical Main Business
Table 131. Sichuan Gowell Pharmaceutical Latest Developments
Table 132. Shenzhen Main Luck Pharmaceuticals Basic Information, Mirabegron Sustained-releaseTablets Manufacturing Base, Sales Area and Its Competitors
Table 133. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-releaseTablets Product Portfolios and Specifications
Table 134. Shenzhen Main Luck Pharmaceuticals Mirabegron Sustained-releaseTablets Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Shenzhen Main Luck Pharmaceuticals Main Business
Table 136. Shenzhen Main Luck Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Mirabegron Sustained-releaseTablets
Figure 2. Mirabegron Sustained-releaseTablets Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Mirabegron Sustained-releaseTablets Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Mirabegron Sustained-releaseTablets Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Mirabegron Sustained-releaseTablets Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Mirabegron Sustained-releaseTablets Sales Market Share by Country/Region (2025)
Figure 10. Mirabegron Sustained-releaseTablets Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 25mg perTablet
Figure 12. Product Picture of 50mg perTablet
Figure 13. Global Mirabegron Sustained-releaseTablets Sales Market Share by Type in 2026
Figure 14. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Type (2021-2026)
Figure 15. Mirabegron Sustained-releaseTablets Consumed in Hospital and Clinic
Figure 16. Global Mirabegron Sustained-releaseTablets Market: Hospital and Clinic (2021-2026) & (K Units)
Figure 17. Mirabegron Sustained-releaseTablets Consumed in Pharmacy
Figure 18. Global Mirabegron Sustained-releaseTablets Market: Pharmacy (2021-2026) & (K Units)
Figure 19. Mirabegron Sustained-releaseTablets Consumed in Other
Figure 20. Global Mirabegron Sustained-releaseTablets Market: Other (2021-2026) & (K Units)
Figure 21. Global Mirabegron Sustained-releaseTablets Sale Market Share by Application (2025)
Figure 22. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Application in 2026
Figure 23. Mirabegron Sustained-releaseTablets Sales by Company in 2026 (K Units)
Figure 24. Global Mirabegron Sustained-releaseTablets Sales Market Share by Company in 2026
Figure 25. Mirabegron Sustained-releaseTablets Revenue by Company in 2026 ($ millions)
Figure 26. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Company in 2026
Figure 27. Global Mirabegron Sustained-releaseTablets Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Mirabegron Sustained-releaseTablets Sales 2021-2026 (K Units)
Figure 30. Americas Mirabegron Sustained-releaseTablets Revenue 2021-2026 ($ millions)
Figure 31. APAC Mirabegron Sustained-releaseTablets Sales 2021-2026 (K Units)
Figure 32. APAC Mirabegron Sustained-releaseTablets Revenue 2021-2026 ($ millions)
Figure 33. Europe Mirabegron Sustained-releaseTablets Sales 2021-2026 (K Units)
Figure 34. Europe Mirabegron Sustained-releaseTablets Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Mirabegron Sustained-releaseTablets Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Mirabegron Sustained-releaseTablets Revenue 2021-2026 ($ millions)
Figure 37. Americas Mirabegron Sustained-releaseTablets Sales Market Share by Country in 2026
Figure 38. Americas Mirabegron Sustained-releaseTablets Revenue Market Share by Country (2021-2026)
Figure 39. Americas Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)
Figure 40. Americas Mirabegron Sustained-releaseTablets Sales Market Share by Application (2021-2026)
Figure 41. United States Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Mirabegron Sustained-releaseTablets Sales Market Share by Region in 2026
Figure 46. APAC Mirabegron Sustained-releaseTablets Revenue Market Share by Region (2021-2026)
Figure 47. APAC Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)
Figure 48. APAC Mirabegron Sustained-releaseTablets Sales Market Share by Application (2021-2026)
Figure 49. China Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 53. India Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Mirabegron Sustained-releaseTablets Sales Market Share by Country in 2026
Figure 57. Europe Mirabegron Sustained-releaseTablets Revenue Market Share by Country (2021-2026)
Figure 58. Europe Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)
Figure 59. Europe Mirabegron Sustained-releaseTablets Sales Market Share by Application (2021-2026)
Figure 60. Germany Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 61. France Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Market Share by Application (2021-2026)
Figure 68. Egypt Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Mirabegron Sustained-releaseTablets in 2026
Figure 74. Manufacturing Process Analysis of Mirabegron Sustained-releaseTablets
Figure 75. Industry Chain Structure of Mirabegron Sustained-releaseTablets
Figure 76. Channels of Distribution
Figure 77. Global Mirabegron Sustained-releaseTablets Sales Market Forecast by Region (2027-2032)
Figure 78. Global Mirabegron Sustained-releaseTablets Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Mirabegron Sustained-releaseTablets Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Mirabegron Sustained-releaseTablets Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Mirabegron Sustained-releaseTablets Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Mirabegron Sustained-releaseTablets Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Mirabegron Sustained-releaseTablets
Figure 2. Mirabegron Sustained-releaseTablets Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Mirabegron Sustained-releaseTablets Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Mirabegron Sustained-releaseTablets Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Mirabegron Sustained-releaseTablets Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Mirabegron Sustained-releaseTablets Sales Market Share by Country/Region (2025)
Figure 10. Mirabegron Sustained-releaseTablets Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 25mg perTablet
Figure 12. Product Picture of 50mg perTablet
Figure 13. Global Mirabegron Sustained-releaseTablets Sales Market Share by Type in 2026
Figure 14. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Type (2021-2026)
Figure 15. Mirabegron Sustained-releaseTablets Consumed in Hospital and Clinic
Figure 16. Global Mirabegron Sustained-releaseTablets Market: Hospital and Clinic (2021-2026) & (K Units)
Figure 17. Mirabegron Sustained-releaseTablets Consumed in Pharmacy
Figure 18. Global Mirabegron Sustained-releaseTablets Market: Pharmacy (2021-2026) & (K Units)
Figure 19. Mirabegron Sustained-releaseTablets Consumed in Other
Figure 20. Global Mirabegron Sustained-releaseTablets Market: Other (2021-2026) & (K Units)
Figure 21. Global Mirabegron Sustained-releaseTablets Sale Market Share by Application (2025)
Figure 22. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Application in 2026
Figure 23. Mirabegron Sustained-releaseTablets Sales by Company in 2026 (K Units)
Figure 24. Global Mirabegron Sustained-releaseTablets Sales Market Share by Company in 2026
Figure 25. Mirabegron Sustained-releaseTablets Revenue by Company in 2026 ($ millions)
Figure 26. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Company in 2026
Figure 27. Global Mirabegron Sustained-releaseTablets Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Mirabegron Sustained-releaseTablets Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Mirabegron Sustained-releaseTablets Sales 2021-2026 (K Units)
Figure 30. Americas Mirabegron Sustained-releaseTablets Revenue 2021-2026 ($ millions)
Figure 31. APAC Mirabegron Sustained-releaseTablets Sales 2021-2026 (K Units)
Figure 32. APAC Mirabegron Sustained-releaseTablets Revenue 2021-2026 ($ millions)
Figure 33. Europe Mirabegron Sustained-releaseTablets Sales 2021-2026 (K Units)
Figure 34. Europe Mirabegron Sustained-releaseTablets Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Mirabegron Sustained-releaseTablets Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Mirabegron Sustained-releaseTablets Revenue 2021-2026 ($ millions)
Figure 37. Americas Mirabegron Sustained-releaseTablets Sales Market Share by Country in 2026
Figure 38. Americas Mirabegron Sustained-releaseTablets Revenue Market Share by Country (2021-2026)
Figure 39. Americas Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)
Figure 40. Americas Mirabegron Sustained-releaseTablets Sales Market Share by Application (2021-2026)
Figure 41. United States Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Mirabegron Sustained-releaseTablets Sales Market Share by Region in 2026
Figure 46. APAC Mirabegron Sustained-releaseTablets Revenue Market Share by Region (2021-2026)
Figure 47. APAC Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)
Figure 48. APAC Mirabegron Sustained-releaseTablets Sales Market Share by Application (2021-2026)
Figure 49. China Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 53. India Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Mirabegron Sustained-releaseTablets Sales Market Share by Country in 2026
Figure 57. Europe Mirabegron Sustained-releaseTablets Revenue Market Share by Country (2021-2026)
Figure 58. Europe Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)
Figure 59. Europe Mirabegron Sustained-releaseTablets Sales Market Share by Application (2021-2026)
Figure 60. Germany Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 61. France Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Mirabegron Sustained-releaseTablets Sales Market Share by Application (2021-2026)
Figure 68. Egypt Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Mirabegron Sustained-releaseTablets Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Mirabegron Sustained-releaseTablets in 2026
Figure 74. Manufacturing Process Analysis of Mirabegron Sustained-releaseTablets
Figure 75. Industry Chain Structure of Mirabegron Sustained-releaseTablets
Figure 76. Channels of Distribution
Figure 77. Global Mirabegron Sustained-releaseTablets Sales Market Forecast by Region (2027-2032)
Figure 78. Global Mirabegron Sustained-releaseTablets Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Mirabegron Sustained-releaseTablets Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Mirabegron Sustained-releaseTablets Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Mirabegron Sustained-releaseTablets Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Mirabegron Sustained-releaseTablets Revenue Market Share Forecast by Application (2027-2032)
